You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5317 Results
Document
Dec 2019
Document
Dec 2019
Document
Dec 2019
Document
Dec 2019
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma
New Drug Funding Program
    Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
aXitinib,
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
lenvatinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2020
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
lenvatinib (Unfunded),
everolimus (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2019
Document
Jan 2020
Document
Jan 2020
Document
Jan 2020
Document
Jan 2020
Document
Jan 2020

Pages